Venous Thromboembolism Therapeutic Market Research Report by Drug Class - Global Forecast to 2025 - Cumulative Impact of COVID-19
Venous Thromboembolism Therapeutic Market Research Report by Drug Class (Direct Thrombin Inhibitors, Factor XA Inhibitors, Heparin, and Vitamin K Antagonists) - Global Forecast to 2025 - Cumulative Impact of COVID-19
May 04, 2021 14:24 ET | Source: ReportLinker ReportLinker Lyon, FRANCE
New York, May 04, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Venous Thromboembolism Therapeutic Market Research Report by Drug Class - Global Forecast to 2025 - Cumulative Impact of COVID-19 - https://www.reportlinker.com/p05911850/?utm source=GNW
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
Anticoagulants Market revenue to cross USD 51 9 Bn by 2027: Global Market Insights Inc yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Caplin Point Laboratories announced that its subsidiary, Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application
(ANDA) Argatroban Injection, 50 mg/50 ml (1 mg/ml) Single-dose vial presentation, a generic therapeutic equivalent version of (RLD), ARGATROBAN INJECTION, of Hikma Pharmaceuticals.
Caplin has received a CGT (Competitive Generic Therapies) Grant for this ANDA and Caplin is the first approved applicant for such competitive generic therapy, as defined in section 505(j)(5)(B)(v)(III) of the FD&C Act.
Therefore, with this approval, Caplin is eligible for 180 days of CGT exclusivity for Argatroban Injection, 50 mg/50 ml (1 mg/ml) Single- Dose Vial, under section 505(j)(5)(B)(v) of the FD&C Act.